Kaletra 100 MG/ 25 MG Oral Tablet
- RxCUI
- 847745
- RxNorm name
- Kaletra 100 MG/ 25 MG Oral Tablet
- Display name
- Kaletra 100 MG/ 25 MG Oral Tablet
- Full name
- Kaletra 100 MG/ 25 MG Oral Tablet
- Term type
- PSN
- Status
- DailyMed mapping
- Updated
- 2026-06-04 23:39:06
UNII Substances#
No records found.
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Kaletra | LOPINAVIR AND RITONAVIR | AbbVie Inc. | 8290add3-4449-4e58-6c97-8fe1eec972e3 | 2023-04-01 | Warnings, Adverse reactions | 847745 |
DailyMed RxNorm Mappings#
| Set ID | RxNorm string | TTY | SPL version | Label | Effective |
|---|---|---|---|---|---|
| 8290add3-4449-4e58-6c97-8fe1eec972e3 | Kaletra 100 MG/ 25 MG Oral Tablet | PSN | 1700 | These highlights do not include all the information needed to use KALETRA safely and effectively. See full prescribing information for KALETRA. KALETRA (lopinavir and ritonavir) tablet, for oral use KALETRA (lopinavir and ritonavir) oral solution Initial U.S. Approval: 2000 | 20230401 |
| 8290add3-4449-4e58-6c97-8fe1eec972e3 | Kaletra 100 MG / 25 MG Oral Tablet | SY | 1700 | These highlights do not include all the information needed to use KALETRA safely and effectively. See full prescribing information for KALETRA. KALETRA (lopinavir and ritonavir) tablet, for oral use KALETRA (lopinavir and ritonavir) oral solution Initial U.S. Approval: 2000 | 20230401 |
| 8290add3-4449-4e58-6c97-8fe1eec972e3 | lopinavir 100 MG / ritonavir 25 MG Oral Tablet [Kaletra] | SBD | 1700 | These highlights do not include all the information needed to use KALETRA safely and effectively. See full prescribing information for KALETRA. KALETRA (lopinavir and ritonavir) tablet, for oral use KALETRA (lopinavir and ritonavir) oral solution Initial U.S. Approval: 2000 | 20230401 |